Get the Stockscreener App
2.43
5.81%
-0.15
Femasys Inc stock is traded at $2.43, with a volume of 103.27K.
It is down -5.81% in the last 24 hours and down -18.46% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$2.58
Open:
$2.53
24h Volume:
103.27K
Relative Volume:
0.15
Market Cap:
$20.35M
Revenue:
$2.38M
Net Income/Loss:
$-12.40M
P/E Ratio:
-0.376
EPS:
-6.4626
Net Cash Flow:
$-18.68M
1W Performance:
-4.71%
1M Performance:
-18.46%
6M Performance:
-76.32%
1Y Performance:
-65.61%
1-Day Range:
$2.42
$2.6164
1-Week Range:
$2.42
$2.69
52-Week Range:
$2.0223
$22.20
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
2.43 | 20.35M | 2.38M | -12.40M | -18.68M | -6.4626 |
ISRG
Intuitive Surgical Inc
|
399.52 | 141.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.23 | 48.82B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
221.89 | 32.01B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
64.56 | 31.21B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.66 | 30.41B | 29.14B | 1.07B | 1.05B | 1.1956 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Laidlaw | Buy |
Femasys Inc Stock (FEMY) Latest News
Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us
Femasys Inc (NASDAQ: FEMY) Share Price, FEMY Stock News, FEMY Share Price & Updates - kalkine.com.au
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care - Yahoo Finance
FEMASYS INC (FEMY) Stock Price & Overview - ChartMill
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio - Yahoo Finance
Femasys Company Profile & Introduction - Moomoo
Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value - GuruFocus
FemasysFiles For Resale Of Up To 28,124,997 Shares Of Common StockSEC Filing - TradingView
Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan
Femasys Inc (FEMY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Femasys Inc (FEMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stonepine group flags new Femasys (NASDAQ: FEMY) position investors will want to size - Stock Titan
Femasys (FEMY) Stock News & Analysis - TechStock²
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com India
For the first time, UNC Health OB/GYNs can offer Femasys fertility care - Stock Titan
Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayValue Stock Ideas - vinanet.vn
Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingVolume Dry Up - vinanet.vn
Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest TradingVolatility Smirk - vinanet.vn
Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan
Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm
Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com
Why Is Femasys Stock Soaring Today?Femasys (NASDAQ:FEMY) - Benzinga
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Stocktwits
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionLow Growth Earnings - Vinanet
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance
FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan
Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com
Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record
Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView
Femasys secures $30 million to advance fertility portfolio - The Pharma Letter
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan
FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31%Earnings Turnaround - vinanet.vn
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Femasys 2Q Loss/Shr $1.33 >FEMY - Moomoo
Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade
Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan
Femasys reports $331,827 Q2 revenue, $4.47M net loss and $30M financing to support U.S. commercial push - TradingView
Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss - Quiver Quantitative
Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing - Stock Titan
Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Femasys (FEMY) gains Rosalind-linked holder with potential 9.99% equity stake - Stock Titan
FEMY: Net loss narrowed and liquidity improved following a $30 million post-quarter financing - TradingView
FEMY Q1 2026 Earnings: Narrower Loss Beats Estimates as Stock Slips 2.55%Earnings Decline Risk - vinanet.vn
FEMY Q1 2026 Earnings: Narrower-Than-Expected Loss of -$1.20 Per Share, Yet Shares Dip 2.34%ROIC Trend Report - Vinanet
Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents - marketscreener.com
Femasys Inc. (FEMY) Q1 2026 Earnings: Narrower-Than-Expected Loss of -$1.20 Per Share Beats Estimates by 34.64% - dars.gov.et
Femasys receives patents for FemBloc birth control polymer By Investing.com - Investing.com South Africa
Femasys receives patents for FemBloc birth control polymer - Investing.com
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
3.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):